EA201692127A1 - ANTIBODIES CONNECTING WITH HUMAN DEC-205 - Google Patents

ANTIBODIES CONNECTING WITH HUMAN DEC-205

Info

Publication number
EA201692127A1
EA201692127A1 EA201692127A EA201692127A EA201692127A1 EA 201692127 A1 EA201692127 A1 EA 201692127A1 EA 201692127 A EA201692127 A EA 201692127A EA 201692127 A EA201692127 A EA 201692127A EA 201692127 A1 EA201692127 A1 EA 201692127A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
human dec
given
description
antibodies connecting
Prior art date
Application number
EA201692127A
Other languages
Russian (ru)
Inventor
Тибор Келер
Личжэнь Хе
Венки Рамакришна
Лаура А. Витейл
Original Assignee
Селлдекс Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40257038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селлдекс Терапьютикс Инк. filed Critical Селлдекс Терапьютикс Инк.
Publication of EA201692127A1 publication Critical patent/EA201692127A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Дано описание изолированных моноклональных антител, которые связываются с DEC-205 человека, и соответствующие композиции на основе антител и молекулы. Также приведено описание фармацевтических композиций, содержащих эти антитела, а также терапевтические и диагностические способы применения этих антител.A description of isolated monoclonal antibodies that bind to human DEC-205 and the corresponding antibody-based compositions and molecules are given. A description is also given of pharmaceutical compositions containing these antibodies, as well as therapeutic and diagnostic methods of using these antibodies.

EA201692127A 2007-11-07 2008-11-07 ANTIBODIES CONNECTING WITH HUMAN DEC-205 EA201692127A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US225307P 2007-11-07 2007-11-07
US19155108P 2008-09-10 2008-09-10

Publications (1)

Publication Number Publication Date
EA201692127A1 true EA201692127A1 (en) 2017-08-31

Family

ID=40257038

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201692127A EA201692127A1 (en) 2007-11-07 2008-11-07 ANTIBODIES CONNECTING WITH HUMAN DEC-205
EA201000770A EA026990B1 (en) 2007-11-07 2008-11-07 Antibodies which bind to human cell dec-205

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201000770A EA026990B1 (en) 2007-11-07 2008-11-07 Antibodies which bind to human cell dec-205

Country Status (18)

Country Link
US (4) US8236318B2 (en)
EP (2) EP2570137A3 (en)
JP (3) JP5701606B2 (en)
KR (2) KR101624751B1 (en)
CN (1) CN101888856B (en)
AU (1) AU2008323848B2 (en)
BR (1) BRPI0820270A2 (en)
CA (1) CA2704583A1 (en)
DK (1) DK2224954T3 (en)
EA (2) EA201692127A1 (en)
ES (1) ES2445755T3 (en)
HK (1) HK1146898A1 (en)
IL (1) IL205393A (en)
MX (1) MX2010005022A (en)
NZ (2) NZ585556A (en)
SG (2) SG10201605208QA (en)
WO (1) WO2009061996A2 (en)
ZA (1) ZA201003101B (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073641A2 (en) * 2003-02-18 2004-09-02 Kevin Slawin Induced activation in dendritic cells
EP1838340B1 (en) 2004-12-22 2018-04-04 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
CA2666667C (en) * 2006-10-19 2023-06-20 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
CA2715044A1 (en) * 2007-02-02 2008-08-14 Baylor Research Institute Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
SG10201605208QA (en) 2007-11-07 2016-08-30 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
CA2732763A1 (en) 2008-08-01 2010-02-04 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
EP3238739B1 (en) 2008-09-22 2020-10-21 Baylor College of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
CN105131112A (en) 2009-08-29 2015-12-09 Abbvie公司 Therapeutic dll4 binding proteins
IN2012DN02368A (en) 2009-09-14 2015-08-21 Baylor Res Insitute
WO2011044452A2 (en) * 2009-10-08 2011-04-14 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
WO2011062634A2 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
KR20180044441A (en) 2010-03-02 2018-05-02 애브비 인코포레이티드 Therapeutic dll4 binding proteins
JP6002659B2 (en) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド Antibodies that bind to human CD27 and uses thereof
CA2795947A1 (en) * 2010-04-16 2011-10-20 Bellicum Pharmaceuticals, Inc. Method for treating solid tumors
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
DE102010039019B4 (en) 2010-08-06 2014-08-07 Technische Universität Dresden Antibodies against 6-sulfo LacNAc positive human dendritic cells and their use
WO2012021834A1 (en) * 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
US11291483B2 (en) 2010-10-20 2022-04-05 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US10525168B2 (en) 2010-10-20 2020-01-07 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11207109B2 (en) 2010-10-20 2021-12-28 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11484627B2 (en) 2010-10-20 2022-11-01 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
WO2012095412A1 (en) * 2011-01-10 2012-07-19 Ct Atlantic Ltd. Combination therapy including tumor associated antigen binding antibodies
EA026524B1 (en) 2011-01-10 2017-04-28 Общество С Ограниченной Ответственностью "Биолаб 612" USE OF Toll-LIKE RECEPTOR AGONIST FOR TREATING CANCER
US20130017151A1 (en) * 2011-07-11 2013-01-17 Baylor Research Institute SUBSETS OF ANTIGEN-PRESENTING CELLS (APCs) IN THE HUMAN VAGINA AND THEIR DISTINCT FUNCTIONS
AR087380A1 (en) * 2011-07-27 2014-03-19 Baylor Res Inst DENDRITIC CELL VACCINES (CD) FOR PANCREAS CANCER THERAPY
UA117097C2 (en) * 2012-03-28 2018-06-25 Санофі Antibodies to bradykinin b1 receptor ligands
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
CN103044552B (en) * 2012-12-11 2019-01-29 中国医学科学院病原生物学研究所 The monoclonal antibody of the anti-surface of dendritic cells DEC-205 molecule of humanization
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
KR20150131218A (en) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. Methods for controlling t cell proliferation
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US9913882B2 (en) 2013-06-05 2018-03-13 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
MX346878B (en) * 2013-06-26 2017-03-28 Univ Nac Autónoma De México New monoclonal antibodies against the receptor dec-205 of chicken dendritic cells.
CN103409451A (en) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 Method for loading tumor antigen peptide to dendritic cell (DC) in targeting manner
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
CN111849912B (en) 2014-02-14 2024-03-15 贝里坤制药股份有限公司 Method for activating T cells using inducible chimeric polypeptides
ES2816630T3 (en) 2014-07-30 2021-04-05 Genome Prot Inc Flagellin compositions and uses
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
EP3206708B1 (en) 2014-10-16 2022-11-02 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
JP6718444B2 (en) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） T cell receptors directed against Bob1 and uses thereof
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
CN107056932B (en) * 2016-12-24 2021-04-09 深圳大学 Amino acid sequence, fusion protein containing OVA epitope, and preparation method and application thereof
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
KR20200006972A (en) 2017-04-14 2020-01-21 톨나인, 인크. Immunomodulatory polynucleotides, antibody conjugates thereof, and methods of use thereof
KR102385495B1 (en) * 2017-10-14 2022-04-15 애브비 인코포레이티드 Anti-CD71 activatable antibody drug conjugates and methods of use thereof
US20200347138A1 (en) * 2017-10-27 2020-11-05 Indian Institute Of Science Dendritic cells-targeting vaccine
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
WO2019244973A1 (en) * 2018-06-20 2019-12-26 中外製薬株式会社 Method for activating immune response of target cell and composition therefor
JP7396275B2 (en) 2018-06-29 2023-12-12 日本ゼオン株式会社 Identification media, authenticity determination methods, and articles
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
CN113366016B (en) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 Monoclonal antibody for resisting human interleukin 5 (IL-5) and application thereof
JP2023503615A (en) * 2019-11-26 2023-01-31 シーダーズ－サイナイ メディカル センター Compositions and methods for treating diseases and conditions by depleting mitochondrial or genomic DNA from circulation
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
JP2023515566A (en) 2020-02-28 2023-04-13 タラック セラピューティクス，インク． Transglutaminase-mediated conjugation
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof
JP2024515560A (en) 2021-04-09 2024-04-10 セルデックス セラピューティクス インコーポレイテッド Antibodies to ILT4, bispecific anti-ILT4/PD-L1 antibodies, and methods of use thereof
KR20240013732A (en) 2021-05-26 2024-01-30 옥스포드 바이오테라퓨틱스 리미티드 Pharmaceutical combination comprising an anti-CD205 antibody and an immune checkpoint inhibitor
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
CN115028741A (en) * 2022-06-21 2022-09-09 苏州工业园区唯可达生物科技有限公司 Tumor antigen-antibody complex, preparation method and application thereof
CN114989311A (en) * 2022-06-21 2022-09-02 苏州工业园区唯可达生物科技有限公司 3G9-LNM antibody coupling protein and preparation method and application thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857090A (en) * 1955-06-02 1958-10-21 Crown Zellerbach Corp Container for heavy articles
US2887389A (en) * 1955-06-03 1959-05-19 Creath Q Linville Cartons
US3164316A (en) * 1962-05-21 1965-01-05 Weyerhaeuser Co Carton
US3353740A (en) * 1965-12-28 1967-11-21 Int Paper Co Reclosable carton
US3447735A (en) * 1967-07-03 1969-06-03 Western Kraft Corp Easy-opening container
US3552633A (en) * 1969-10-27 1971-01-05 Inland Container Corp Pallet case
US3698548A (en) * 1970-06-15 1972-10-17 Robert N Stenzel Box for dispensing flexible sheet material
US3883067A (en) * 1972-12-15 1975-05-13 Continental Can Co Carton corner construction
US4267959A (en) * 1979-10-22 1981-05-19 Westvaco Corporation Hinged paperboard container
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (en) * 1987-05-21 2005-08-25 Micromet Ag MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CN1074422C (en) 1987-11-18 2001-11-07 希龙股份有限公司 Nanbv diagnostics and vaccines
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ATE149841T1 (en) * 1990-01-26 1997-03-15 Immunomedics Inc VACCINES AGAINST CANCER AND INFECTIOUS DISEASES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992007579A1 (en) 1990-11-06 1992-05-14 The Children's Medical Center Corporation Soluble mannose receptor peptides
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
JPH06508880A (en) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト Thermotropic liquid crystal segmented block copolymer
DE4123760C2 (en) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreactive areas on the HPV 16 proteins E1 and E2
GB9117522D0 (en) 1991-08-14 1991-10-02 Medical Res Council Ligands for dendritic cells, their uses and production
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995012409A1 (en) * 1993-11-04 1995-05-11 Canterbury Health Limited Dendritic cell-specific antibodies and methods for their preparation
WO1995015340A1 (en) 1993-12-03 1995-06-08 The Board Of Trustees Of Leland Stanford Junior University Monoclonal antibodies to antigens expressed by human dendritic cells
US5541110A (en) * 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
EP0808366A1 (en) 1995-01-31 1997-11-26 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
ATE332372T1 (en) * 1996-05-29 2006-07-15 Derek Nigel John Hart RECEPTOR OF DENDRITIC CELLS.
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6069233A (en) 1996-10-03 2000-05-30 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO1998015579A1 (en) 1996-10-09 1998-04-16 Canterbury Health Limited Dendritic cell-specific antibodies
CN100391973C (en) * 1997-07-09 2008-06-04 先灵公司 Isolated dendritic cell membrane protein genes
DK1027063T3 (en) 1997-09-29 2009-06-02 Macfarlane Burnet Inst For Med Mannose receptor-carrying cell line and antigen composition
AU1457199A (en) * 1997-11-12 1999-05-31 University Of Pittsburgh Isolation, characterization, and identification of dendritic like cells and methods of using same
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JP2002506645A (en) 1998-03-17 2002-03-05 シェーリング コーポレイション Isolated mammalian membrane protein genes and related reagents
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
CA2328415A1 (en) 1998-05-11 1999-11-18 Micromet Gmbh Antibodies to dendritic cells and human dendritic cell populations and uses thereof
AU4954899A (en) 1998-06-26 2000-01-17 Trustees Of Dartmouth College Methods and compositions for modulating antigen-specific immunological (humoral)responses by targeting such antigen to apcs in conjunction with anti-cd40 ligan d administration
KR100295558B1 (en) 1998-06-27 2001-07-12 김기태 Among the primary immune cells, the monoclonal antibody 3-6-A (dendritic cell), which specifically acts on the surface of dendritic cells
EP0997476A3 (en) 1998-09-25 2000-07-19 Schering-Plough Antibodies to a mammalian Langerhans cell antigen and their uses
DE60014588T2 (en) * 1999-02-18 2006-02-23 F. Hoffmann-La Roche Ag THIOAMIDDERIVATE
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6774226B1 (en) 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
CA2406378A1 (en) * 2000-04-12 2001-10-25 University Of Rochester Targeted vaccine delivery systems
US7201714B2 (en) * 2000-04-27 2007-04-10 Graphic Packaging International, Inc. Paperboard cartons with laminated reinforcing ribbons and method of printing same
EP1282646B1 (en) 2000-05-08 2012-04-11 Celldex Research Corporation Human monoclonal antibodies to dendritic cells
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
EP1451226A1 (en) * 2001-11-30 2004-09-01 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
WO2004026326A2 (en) 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
CN1767852B (en) * 2003-01-31 2010-04-14 塞尔德克斯医疗公司 Antibody vaccine conjugates and uses therefor
JP2006521387A (en) 2003-03-04 2006-09-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド Method of treating autoimmune disease by induction of antigen presentation by tolerance-inducing antigen-presenting cells
US6834793B2 (en) * 2003-05-31 2004-12-28 Graphic Packaging International, Inc. Enclosed container carton convertible into a tray
US20070026057A1 (en) 2003-08-21 2007-02-01 Lipotek Pty Ltd. In vivo targeting of dendritic cells
KR100918746B1 (en) * 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 Anti-a33 antibody
CA2623406C (en) * 2005-09-21 2011-11-15 Graphic Packaging International, Inc. Reinforced cartons
NZ568015A (en) * 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
EP1957539B1 (en) * 2005-12-08 2013-04-17 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
SG10201605208QA (en) 2007-11-07 2016-08-30 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
JP6136343B2 (en) 2012-06-12 2017-05-31 株式会社リコー Information processing system, information processing method, program, and recording medium
KR102264548B1 (en) 2014-11-21 2021-06-16 삼성전자주식회사 Semiconductor packages and fabrication method thereof

Also Published As

Publication number Publication date
KR101811965B1 (en) 2017-12-22
CN101888856A (en) 2010-11-17
SG187482A1 (en) 2013-02-28
NZ585556A (en) 2012-07-27
US20090175880A1 (en) 2009-07-09
EA201000770A1 (en) 2010-12-30
US20100098704A1 (en) 2010-04-22
KR101624751B1 (en) 2016-05-27
EP2224954A2 (en) 2010-09-08
JP2011503014A (en) 2011-01-27
US20120309031A1 (en) 2012-12-06
IL205393A0 (en) 2010-12-30
AU2008323848A1 (en) 2009-05-14
EP2570137A2 (en) 2013-03-20
JP5701606B2 (en) 2015-04-15
WO2009061996A2 (en) 2009-05-14
DK2224954T3 (en) 2014-03-03
US8586720B2 (en) 2013-11-19
US9624300B2 (en) 2017-04-18
SG10201605208QA (en) 2016-08-30
EP2224954B1 (en) 2014-01-08
KR20160017128A (en) 2016-02-15
US20130101593A1 (en) 2013-04-25
JP2015083010A (en) 2015-04-30
CN101888856B (en) 2014-08-27
MX2010005022A (en) 2010-06-02
JP2017014218A (en) 2017-01-19
AU2008323848B2 (en) 2014-09-25
BRPI0820270A2 (en) 2015-06-16
JP6067667B2 (en) 2017-01-25
US8236318B2 (en) 2012-08-07
HK1146898A1 (en) 2011-07-22
NZ599777A (en) 2013-09-27
CA2704583A1 (en) 2009-05-14
US8362214B2 (en) 2013-01-29
EA026990B1 (en) 2017-06-30
KR20100100857A (en) 2010-09-15
EP2570137A3 (en) 2013-08-21
ES2445755T3 (en) 2014-03-05
IL205393A (en) 2015-04-30
ZA201003101B (en) 2014-10-29
WO2009061996A3 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
EA201692127A1 (en) ANTIBODIES CONNECTING WITH HUMAN DEC-205
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
EA200702053A1 (en) ANTIBODIES AGAINST CD38 FOR THE TREATMENT OF MULTIPLE MYELOMA
EA201201273A1 (en) MONOCLONAL ANTIBODIES TO C-MET
EA200800812A1 (en) Antibody Anti-CD3 Compositions
CY1120413T1 (en) SPECIALLY HUMANIZED ANTIBODIES IN THE PROTEINOLOGICAL FORM OF BETA-AMYLOID Peptide
EA201291039A1 (en) HUMAN CD27 ANTIBODIES AND THEIR APPLICATION
UA118332C2 (en) Cs27l antigen binding proteins
EA201390993A1 (en) ANTIBODIES TO CD38
UA115402C2 (en) CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3
EA201190041A1 (en) HUMAN AUTOANTIBODIES AGAINST ALPHA-SINUCLEIN
EA201391761A1 (en) ANTI-ALPHA-SINUCLAIN-BINDING MOLECULES
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201591020A1 (en) HUMAN ANTI-TAU ANTIBODIES
EA201270813A1 (en) ANTIBODIES TO N3pGlu BETA AMYLOID PEPTIDE AND THEIR APPLICATION
EA201170716A1 (en) ANTIBODIES TO C-MET
EA201300016A1 (en) HUMAN ANTIBODY CONJUGATES AGAINST TISSUE FACTOR WITH DRUGS
EA201190018A1 (en) MYOSTATINCONNECTING PROTEINS
EA201270571A1 (en) HUMAN IL-23 ANTIGEN-BINDING PROTEINS
UA107490C2 (en) TNF-a-BINDING PROTEINS
EA200800952A1 (en) CONJUGATES ANTIBODY-DRUG AND METHODS OF APPLICATION
EA201290570A1 (en) CONSTRUCTIONS CONNECTING WITH RON AND METHODS OF THEIR USE
IN2014CN03936A (en)
EA201490825A8 (en) TDP-43-SPECIFICALLY BINDING MOLECULES
EA200870021A1 (en) HUMAN MONOCLONAL ANTIBODIES TO FUKOZIL-GM1 AND METHODS OF APPLICATION OF ANTI-FUKOSIL-GM1 ANTIBODIES